Abexinostat is an inhibitor of histone deacetylase (HDAC). While it primarily targets HDAC1, it also shows activity against HDAC2, 3, 6, 8, and 10. Abexinostat has shown synergistic effect with bortezomib in lymphoma cells, inducing caspase-dependent apoptosis in vitro. It has exhibited efficacy when used in combination with doxorubicin against metastatic sarcoma.
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...



































